Publications by authors named "Nikeshan Jeyakumar"

Claim this Profile
C
Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.
Hrishikesh K Srinagesh, Anne Marijn Kramer, John H Baird, Agnes Reschke, Bita Sahaf, Nikeshan Jeyakumar

Blood Cancer Discov· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, Amy Zhang, Katharine Miller, Nikeshan Jeyakumar

Bone Marrow Transplant· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.
Yannis K Valtis, Chenyu Lin, David Nemirovsky, Sean M Devlin, Kai Rejeski, Nikeshan Jeyakumar

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies.
Alexandra Dreyzin, Anne Marijn Kramer, Bonnie Yates, Hao-Wei Wang, Bita Sahaf, Nikeshan Jeyakumar

Cytotherapy· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement.
Ibrahim N Muhsen, Gregory W Roloff, Rawan Faramand, Tamer Othman, Yannis Valtis, Nikeshan Jeyakumar

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy.
Hannah Lust, Liora M Schultz, Soyang Kwon, Gregory W Roloff, Ibrahim Aldoss, Nikeshan Jeyakumar

Blood Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker, Nikeshan Jeyakumar

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin, Nikeshan Jeyakumar

Blood Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.
Hrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, Nikeshan Jeyakumar, Mark Hamilton

Blood· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Liora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, Bita Sahaf, Hrishi Srinagesh

Leukemia· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Nikeshan Jeyakumar, Melody Smith

Front Immunol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Clinical and Molecular Characterization of -Mutant Colorectal Cancer.
Jason T Henry, Oluwadara Coker, Saikat Chowdhury, John Paul Shen, Van K Morris, Nikeshan Jeyakumar

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia.
Nikeshan Jeyakumar, Ibrahim Aldoss, Dongyun Yang, Sally Mokhtari, Ketevan Gendzekhadze

Eur J Haematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma.
Nikeshan Jeyakumar, Mikel Etchegaray, Jason Henry, Laura Lelenwa, Bihong Zhao

Case Reports Immunol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients.
Jose F Camargo, Erik Kimble, Rossana Rosa, Luis A Shimose, Maria X Bueno, Nikeshan Jeyakumar

Biol Blood Marrow Transplant· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers to the universal adoption of bilateral internal mammary artery grafting.
Jeremiah Umakanthan, Panch Jeyakumar, Branavan Umakanthan, Nikeshan Jeyakumar, Nadarajah Senthilkumar

Int J Surg· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis